Remuneration report

In accordance with the specifications of the Act Implementing the Second Shareholders’ Rights Directive (ARUG II) in conjunction with Section 162 AktG (version dated 22 December 2020), the Management Board and Supervisory Board of Carl Zeiss Meditec AG report on the remuneration granted and owed to the members of the Management Board and Supervisory Board for fiscal year 2024/25. The accrual principle applies: Remuneration is considered granted as soon as it has actually accrued to the member of the executive body and has been transferred to their assets.

This report explains the key components of the remuneration system approved by the Annual General Meeting on 22 March 2023, and meets the regulatory requirements of the German Stock Corporation Act. It is also based on the recommendations of the German Corporate Governance Code (DCGK 2002). To ensure transparency and accuracy, the Management Board and Supervisory Board commissioned a substantive audit by PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft in addition to the formal audit required by law.

In line with the principle of “pay for performance”, the remuneration of the Management Board is closely linked to the performance and success of the Company.